Transplantation for liver tumors.

abstract：:Recent changes to the staging of melanoma, coupled with advances in surgical and medical treatment, have resulted in new methods for diagnostic evaluation and reporting of melanocytic lesions by pathologists. This review provides an update on recent changes in evaluation and reporting of primary melanoma, evaluation o...

journal_title：Seminars in oncology

authors： Mathew R,Messina JL

更新日期：2012-04-01 00:00:00

abstract：:It is well known that African American men are more likely to be diagnosed with metastatic prostate cancer than White men. Racial variation in the use of prostate cancer early detection modalities (ie, digital rectal examination [DRE] and prostate-specific antigen [PSA] testing) has been suggested as a major reason fo...

journal_title：Seminars in oncology

authors： Myers RE

更新日期：1999-08-01 00:00:00

abstract：:Complications due to cancer and its treatment are common and increase in incidence and severity as the disease progresses. Central nervous system complications affect 15% to 20% of patients, and up to 75% have bone metastases at some point during the disease process. Endocrine abnormalities include hypercalcemia, adre...

journal_title：Seminars in oncology

authors： Nelson KA,Walsh D,Abdullah O,McDonnell F,Homsi J,Komurcu S,LeGrand SB,Zhukovsky DS

更新日期：2000-02-01 00:00:00

abstract：:Because studies of breast cancer patients and their relatives provide statistical evidence for involvement of autosomal dominant genes, the identification of specific genetic effects has long been the focus of efforts to identify women at exceedingly high risk. BRCA1, a gene that confers greatly increased susceptibili...

journal_title：Seminars in oncology

authors： Cannon-Albright LA,Skolnick MH

更新日期：1996-02-01 00:00:00

abstract：:A trial of combination chemotherapy using mitoxantrone-cyclophosphamide was started in 1983. Sixteen patients with widely metastatic cancer of the breast, including one man, received mitoxantrone, 10 mg/m2 intravenously (IV) over 30 minutes on day 1, followed by cyclophosphamide, 200 mg/m2 by mouth (PO) daily in divid...

journal_title：Seminars in oncology

authors： McDonald DB,Abu-Zahra H,Yoshida S,Binder H

更新日期：1984-09-01 00:00:00

abstract：:Among the various deleterious effects of cancer chemotherapy, vascular toxicity is the least well recognized. This lack of recognition may be because the vasculotoxic phenomena are not unique to antineoplastic agents, can occur in patients without exposure to these agents, and the fact cancer itself may produce a hype...

journal_title：Seminars in oncology

authors： Shahab N,Haider S,Doll DC

更新日期：2006-02-01 00:00:00

abstract：:Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has been shown to be an effective agent in the treatment of metastatic breast carcinoma. This multicenter randomized study compared paclitaxel 175 mg/m2 given as a 3-hour infusion every 3 weeks with mitomycin 12 mg/m2 given as an intravenous infusion ever...

journal_title：Seminars in oncology

authors： Dieras V,Marty M,Tubiana N,Corette L,Morvan F,Serin D,Mignot L,Chazard M,Garet F,Onetto N

更新日期：1995-08-01 00:00:00

abstract：:The goal of this National Cancer Institute-sponsored phase I trial is to determine the feasibility, toxicity, and pharmacokinetics of continuous-infusion (24 hr/d, 7 d/wk, 7 weeks total) intravenous paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) when combined with standard, curative-intent radiation t...

journal_title：Seminars in oncology

authors： Rosenthal DI,Okani O,Corak J,Kavanaugh D,Kamen B,Vuitch FM,Gazdar AF,Greiner J,Frenkel EF,Carbone DP

更新日期：1997-08-01 00:00:00

abstract：:Cancer cells that express excessive levels of Bcl-2 pose a major problem in the delivery of curative therapy. Most treatments for such cancer involve chemotherapy to induce the apoptotic process. While these therapies often result in disease control for periods of time, failure to initiate apoptosis as a result of acq...

journal_title：Seminars in oncology

authors： Cotter FE

更新日期：2004-12-01 00:00:00

abstract：:Recent studies have indicated that bone marrow angiogenesis is increased in multiple myeloma, suggesting that treatment with an antiangiogenic agent might be useful. Among the new antiangiogenic drugs in development, Neovastat (AE-941; Aeterna Laboratories, Quebec City, Canada) can be classified as a naturally occurri...

journal_title：Seminars in oncology

authors： Falardeau P,Champagne P,Poyet P,Hariton C,Dupont E

更新日期：2001-12-01 00:00:00

abstract：:In order to correlate changes in morphology to changes in molecular attributes, we constructed a tissue microarray of thin and thick melanomas selected to represent progression from dysplasia to early and advanced melanoma. Hematoxylin and eosin (H&E) staining and immunohistology with antibodies to cyclin D1, p16, Ki6...

journal_title：Seminars in oncology

authors： Tuthill RJ,Reed RJ

更新日期：2007-12-01 00:00:00

abstract：:The ability of dexrazoxane (DEX) to protect against doxorubicin (DOX)-induced cardiomyopathy has been demonstrated in mice, normotensive and hypertensive rats, rabbits, dogs, swine, and humans. These animal models of DOX-induced cardiomyopathy were found to be highly predictive of DEX activity clinically. In mice admi...

journal_title：Seminars in oncology

authors： Imondi AR

更新日期：1998-08-01 00:00:00

abstract：:Etoposide has been used in the treatment of a wide variety of neoplasms, including small cell lung cancer. Kaposi's sarcoma, testicular cancer, acute leukemia, and lymphoma. Its current therapeutic use is limited by myelosuppression, particularly neutropenia. Pharmacodynamic studies of etoposide show that this toxicit...

journal_title：Seminars in oncology

authors： Kobayashi K,Ratain MJ

更新日期：1992-12-01 00:00:00

abstract：:Richter syndrome (RS) is the development of an aggressive lymphoma in patients with a previous or concomitant diagnosis of chronic lymphocytic leukemia (CLL). The incidence rate RS is ~0.5% per year of observation. Two biomarkers (NOTCH1 mutations and subset 8 configuration of the B-cell receptor) may help identifying...

journal_title：Seminars in oncology

authors： Rossi D,Gaidano G

更新日期：2016-04-01 00:00:00

abstract：:Almost 125 years after the first documented case, pulmonary metastasectomy is still poorly understood. No other organ is subject to the wide histologic variety of metastatic insults, and this fact has complicated a complete exposition of when pulmonary metastasectomy may be beneficial. Many physicians still consider p...

journal_title：Seminars in oncology

authors： Sternberg DI,Sonett JR

更新日期：2007-06-01 00:00:00

abstract：:The liver is the most common site of metastatic colorectal cancer (CRC) and the status of this organ is an important determinant of overall survival in patients with advanced disease. Complete resection of hepatic CRC metastases can provide a long-term cure for some patients, but the majority of liver metastases are n...

journal_title：Seminars in oncology

authors： Ruan DT,Warren RS

更新日期：2005-02-01 00:00:00

abstract：:Vinorelbine, a vinca alkaloid, was the first drug in over 20 years to be approved by the Food and Drug Administration for treatment of advanced non-small cell lung cancer (NSCLC). The drug's nonhematologic toxicities are usually mild; its dose-limiting toxicity is neutropenia. Vinorelbine has been studied in many phas...

journal_title：Seminars in oncology

authors： Wozniak AJ

更新日期：1999-10-01 00:00:00

abstract：:Advanced-stage mantle cell lymphoma (MCL) is a disease for which no curative treatment strategy exists. Results with standard combination chemotherapy, with or without an anthracycline, are disappointing, and new and better therapies are needed. High-dose therapy and autologous stem-cell transplantation (ASCT) have be...

journal_title：Seminars in oncology

authors： Mangel J,Buckstein R,Imrie K,Spaner D,Crump M,Tompkins K,Reis M,Perez-Ordonez B,Deodhare S,Romans R,Pennell N,Robinson JB,Hewitt K,Richardson P,Lima A,Pavlin P,Berinstein NL

更新日期：2002-02-01 00:00:00

abstract：:Glioblastoma multiforme (GBM) is the most common form of primary malignant brain cancer. Median overall survival (OS) for newly diagnosed patients is only about 12 to 18 months. GBM tumors invariably recur, and there is no widely recognized and effective standard treatment for recurrent GBM. NovoTTF Therapy is a novel...

journal_title：Seminars in oncology

authors： Vymazal J,Wong ET

更新日期：2014-10-01 00:00:00

abstract：:The role of radiation therapy in the management of breast cancer continues to evolve. For patients with early stage breast cancer, hypofractionated whole breast irradiation following breast conserving surgery now represents the standard of care based on randomized data with long-term efficacy and toxicity outcomes. Pa...

journal_title：Seminars in oncology

authors： Shah C,Bauer-Nilsen K,McNulty RH,Vicini F

更新日期：2020-08-01 00:00:00

abstract：:Compelling data implicate angiogenesis and tumor-associated neovascularization as a central pathogenic step in the process of tumor growth, invasion, and metastasis. These complex processes involve multiple steps and pathways dependent on the local balance between positive and negative regulatory factors, as well as i...

journal_title：Seminars in oncology

authors： Pluda JM

更新日期：1997-04-01 00:00:00

abstract：:The medical treatment of squamous cell cervical carcinoma is receiving increasing attention. Cisplatin and ifosfamide are known effective drugs. Paclitaxel has been tested with interesting results in cervical cancer. We evaluated the toxic effects and the antitumor activity of a multiagent regimen that included paclit...

journal_title：Seminars in oncology

authors： Zanetta G,Fei F,Mangioni C

更新日期：2000-02-01 00:00:00

abstract：:The humanized anti-p185(HER2) monoclonal antibody trastuzumab has been shown to effectively inhibit the growth of HER2-overexpressing breast cancer cells in vivo and in vitro. The treatment of cancer cells with trastuzumab results in downregulation of the HER2 receptor. Further downstream cellular events include the a...

journal_title：Seminars in oncology

authors： Baselga J,Albanell J,Molina MA,Arribas J

更新日期：2001-10-01 00:00:00

abstract：:A large meta-analysis showed that chemotherapy results in significant prolongation of survival for patients with non-small cell lung cancer (NSCLC). Pemetrexed is a new multitargeted antifolate chemotherapeutic agent that has shown activity in NSCLC and appears to be similar to the third-generation antitumor agents cu...

journal_title：Seminars in oncology

authors： Shepherd FA

更新日期：2002-12-01 00:00:00

abstract：:Imaging prostate cancer continues to represent a clinical challenge for both primary and recurrent disease. In the evaluation of the persistent/recurrent/metastatic prostate cancer, knowledge of cancer location (local v distant), size, and extent are essential in order to design a treatment, tailored to each patient's...

journal_title：Seminars in oncology

authors： Hricak H,Schöder H,Pucar D,Lis E,Eberhardt SC,Onyebuchi CN,Scher HI

更新日期：2003-10-01 00:00:00

abstract：:Cancer clinical trials represent an important option for patients with a diagnosis of cancer and the clinician-investigators involved in their care who seek options for their disease. For all who are impacted by cancer, these studies offer opportunities for greater learning. Conducting these important studies involves...

journal_title：Seminars in oncology

authors： Schiller SJ,Shannon C,Brophy MT,Denicoff AM,Good MJ,Prindiville SA,Huang GD

更新日期：2019-01-01 00:00:00

abstract：:Docetaxel is a semisynthetic taxane that acts primarily by promoting microtubule assembly and preventing the depolymerization of assembled microtubules, thereby inducing mitotic block and inhibition of cell proliferation. This agent also induces apoptosis and appears to prevent angiogenesis. Although docetaxel has sho...

journal_title：Seminars in oncology

authors： Bekaii-Saab TS,Villalona-Calero MA

更新日期：2005-04-01 00:00:00

abstract：:Pathologic complete response after neoadjuvant chemoradiation therapy is associated with increased survival in esophageal cancer. Early detection of response or nonresponse to neoadjuvant chemoradiation might allow individualization of treatment strategies and avoidance of unnecessary treatment. Positron emission tomo...

journal_title：Seminars in oncology

authors： Chao KS

更新日期：2006-12-01 00:00:00

abstract：:The human gammaherpesvirus family includes Epstein-Barr virus (EBV) and human herpesvirus (HHV)-8, also known as Kaposi sarcoma-associated herpesvirus (KSHV). In human immunodeficiency virus (HIV)-infected patients, both EBV and KSHV have been implicated in the development of a wide range of tumors. KSHV-associated di...

journal_title：Seminars in oncology

authors： Pinzone MR,Berretta M,Cacopardo B,Nunnari G

更新日期：2015-04-01 00:00:00

abstract：:Much recent debate has focused on the optimal classification of epithelial neuroendocrine tumors (NETs). Multiple different systems of terminology, grading, and staging have been proposed, and some systems combine elements of grade and stage into a single prognostic classification. Recently, national and international...

journal_title：Seminars in oncology

authors： Klimstra DS

更新日期：2013-02-01 00:00:00